La Jolla Pharmaceutical Company is dedicated to the creation and marketing of therapeutic solutions, with the ultimate goal of enhancing patient outcomes in the face of life-threatening illnesses. The company's commercialized offerings include GIAPREZA, a potent vasoconstrictor designed to raise blood pressure in adult patients afflicted by septic or other forms of distributive shock. Additionally, it provides XERAVA, a tetracycline-class antibacterial effective in treating complex intra-abdominal infections in individuals aged 18 and above. These vital medications are supplied to hospitals and other healthcare institutions exclusively within the United States. Looking ahead, La Jolla is actively advancing several investigational drug candidates through early-stage clinical or preclinical development. These encompass TP-6076, an intravenous fluorocycline derivative targeting specific multidrug-resistant gram-negative bacteria; TP-271, a fluorocycline available for both intravenous and oral administration, intended to address respiratory conditions stemming from bacterial biothreats, antibiotic-resistant public health pathogens, and community-acquired bacterial pneumonia; and TP-2846, an intravenous tetracycline being explored for its potential in treating acute myeloid leukemia. The company has forged key strategic partnerships, including a licensing agreement with Everest Medicines Limited for the development and commercialization of XERAVA. Furthermore, it holds a similar agreement with PAION AG for the commercialization of both GIAPREZA and XERAVA. Founded in 1989 and headquartered in Waltham, Massachusetts, La Jolla Pharmaceutical Company has operated as a subsidiary of Innoviva, Inc. since August 22, 2022.